Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125298341 | 12529834 | 1 | I | 201606 | 0 | 20160705 | 20160705 | DIR | 51.00 | YR | F | N | 0.00000 | 20160701 | N | PH | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125298341 | 12529834 | 1 | PS | SOMATULINE AUTOGEL | LANREOTIDE ACETATE | 1 | Subcutaneous | D | D | K18580 | 20170712 | 0 | 90 | MG | QM | ||||
125298341 | 12529834 | 3 | C | NORVASC | AMLODIPINE BESYLATE | 1 | 0 | ||||||||||||
125298341 | 12529834 | 4 | C | LISINOPRIL. | LISINOPRIL | 1 | 0 | ||||||||||||
125298341 | 12529834 | 6 | C | ZETIA | EZETIMIBE | 1 | 0 | ||||||||||||
125298341 | 12529834 | 8 | C | MAGNESIUM | MAGNESIUM | 1 | 0 | ||||||||||||
125298341 | 12529834 | 10 | C | TYLENOL | ACETAMINOPHEN | 1 | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125298341 | 12529834 | 1 | Small intestine carcinoma |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125298341 | 12529834 | Diarrhoea | |
125298341 | 12529834 | Headache |
Reporting Sources (this data is often not reported and may therefore be missing here)
Event ID | CASEID | RPSR COD |
---|---|---|
125298341 | 12529834 | HP |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125298341 | 12529834 | 1 | 20160610 | 0 |